Status:

UNKNOWN

A Retrospective Study on the Treatment Pattern and Clinical Prognosis of Severe Tuberculosis Patients

Lead Sponsor:

Tongji Hospital

Conditions:

Tuberculosis

Eligibility:

All Genders

Brief Summary

This is a retrospective clinical study to analyze the clinical characteristics, complications, and effects of different treatment options on long-term prognosis of severe tuberculosis patients. All ca...

Eligibility Criteria

Inclusion

  • For patients with severe pulmonary tuberculosis, imaging and grading diagnosis meet any of the following:
  • Damaged lung ≥ 1 lobe
  • Chest CT shows lesions in ≥3 lung lobes
  • Hematogenous disseminated pulmonary tuberculosis
  • caseous pneumonia
  • bronchial tuberculosis
  • Multiple hilar or mediastinal lymph node enlargement in primary pulmonary tuberculosis
  • Rifampicin-resistant, multidrug-resistant, polydrug-resistant or pan-drug-resistant tuberculosis
  • Combined more than 2 cavities over 8mm
  • Tuberculous massive hemoptysis
  • Pulmonary tuberculosis complicated with acute infection (including multidrug-resistant bacterial infection, fungal infection or multiple infection)
  • Combined with extrapulmonary tuberculosis
  • Intracranial tuberculosis, spinal cord and/or meningeal tuberculosis
  • Pleural effusion, pericardial effusion
  • Empyema or empyema, hemopneumothorax, tracheobronchopleural fistula and severe infection.
  • Heart failure caused by cardiac tamponade or constrictive pericarditis
  • Multiple sites of lymphatic tuberculosis or surgery is necessary
  • Cervical lymphatic tuberculosis
  • Mediastinal lymphatic tuberculosis
  • Abdominal or retroperitoneal lymph node tuberculosis
  • Abdominal tuberculosis, tuberculous peritonitis (ascites or multiple serous cavities)
  • Intestinal tuberculosis causes complete or incomplete intestinal root obstruction or perforation or massive bleeding or severe abdominal infection
  • Gastrointestinal hemorrhage caused by tuberculosis of the digestive system, etc.
  • Musculoskeletal tuberculosis
  • Spinal (cervical, thoracic, lumbar, sacral) tuberculosis
  • Bones in other parts
  • Merge surrounding abscess
  • Urinary or renal tuberculosis
  • Renal failure or damaged blood vessels caused by renal tuberculosis
  • Ureteral stenosis or blockage caused by urinary tuberculosis
  • Adrenal tuberculosis in hypoadrenal insufficiency
  • Liver tuberculosis
  • Age and gender are not limited.

Exclusion

  • Patients with no clear diagnosis at discharge.
  • Patients judged by the investigator to be unsuitable for inclusion in this protocol.
  • The discharge diagnosis was central nervous system tuberculosis, or tuberculous meningitis, or tuberculous cerebrospinal meningitis, or tuberculous meningoencephalitis, or tuberculous encephalitis, or tuberculous brain abscess, or spinal tuberculosis, or tuberculous Hydrocephalus, and is currently participating in other clinical studies.

Key Trial Info

Start Date :

January 13 2018

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

February 1 2024

Estimated Enrollment :

900 Patients enrolled

Trial Details

Trial ID

NCT06021041

Start Date

January 13 2018

End Date

February 1 2024

Last Update

September 1 2023

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology

Wuhan, Hubei, China, 430030

2

Wuhan Pulmonary Hospital(Wuhan Institute for Tuberculosis Control)

Hubei, Wuhan, China, 430030